About
    Novo Group
    Leadership
    Responsibility
    Novo Nordisk Foundation
  • About
  • Investments
    Areas
    Life Science
    Seed InvestmentsVenture InvestmentsGrowth InvestmentsPrincipal InvestmentsPlanetary Health Investments
    Capital Investments
    Strategy
    Regions
    North AmericaEuropeAsia
    Portfolio
  • Investments
  • People
    Careers
    Open positions
  • People & Careers
  • News & Reports
    Facts & Figures
    Media Library
    Contact Public Relations
  • News & Reports

Britt Meelby Jensen

Departments

Board of Directors, Advisory Group

Position

Board Member

Member of the Board since 2022.

Britt Meelby Jensen was born in 1973 and is a Danish national. She received a MSc in International Marketing and Management from Copenhagen Business School in Denmark and furthermore received an MBA from Solvay Business School (Université Libre de Bruxelles) in Brussels.

Between 2000-2002, Britt Meelby Jensen worked as a Management Consultant in McKinsey & Company. She joined Novo Nordisk A/S in 2002 where she held several leadership roles, including being Corporate Vice President of Global Marketing, Market Access & Commercial Excellence. In 2013, Britt Meelby Jensen was appointed CEO of Dako A/S, a global cancer diagnostics company owned by Agilent Inc. From 2015-2019, she was President and CEO of the Danish public biotech company, Zealand Pharma A/S, where the company was listed on Nasdaq in the US. From 2019-2022, Britt Meelby Jensen served as CEO of Swedish Medtech company, Atos Medical AB, owned by PAI partners, however, in connection with selling the company to Coloplast, Britt decided to step down from her role and continued as an advisor. In May 2022, Britt Meelby Jensen was appointed as CEO of Ambu A/S where had served as Board member since 2019.

Other Board Positions and Management Duties:

  • CEO, Ambu A/S, Denmark

  • Advisor, Novo Holdings A/S Advisory Group (NAG), Denmark.

  • Board Member, Hempel Foundation and Hempel Invest A/S, Denmark

Investing to benefit people and the planet

Novo Holdings A/S

Tuborg Havnevej 19

2900 Hellerup Denmark

+45 3527 6500

Email: Info@novoholdings.dk

CVR# 24257630

Media Relations

Christian Mostrup Scheel

Head of Public Relations

Email: novoholdingsmedia@novo.dk

+45 3067 4805

Novo Holdings US Inc.*

Boston:

200 Clarendon Street, Floor 45

Boston, MA 02116 USA

San Francisco:

One Market Plaza, Floor 17 of the Steuart Tower

San Francisco, CA 94105 USA

+1 (415) 552-6686

Email: Info@novoholdings.dk

Novo Holdings Equity Asia Pte. Ltd.*

#40-01, 6 Battery Road

Singapore 049909

Email: Info@novoholdings.dk

Novo Holdings (UK office)

16 Berkeley Street

London W1J 8DZ

Email: Info@novoholdings.dk

Privacy noticeCode of ConductWhistleblowerArticles of association Policy on data ethicsElectronic invoicingDiversity policy

*Novo Ventures (US) Inc., Novo Holdings US Inc., comprising Novo Growth and Principal Investments, and Novo Holdings Equity Asia Pte. Ltd. are separate legal entities that provide certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.

Follow us